Novartis AG Total Liabilities

Latest as of March 2026: CHF79.84 Billion CHF ≈ $100.94 Billion USD

Novartis AG total liabilities. Based on the latest financial reports, Novartis AG (NOVN) has total liabilities worth CHF79.84 Billion CHF (≈ $100.94 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Novartis AG (NOVN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Novartis AG (1998–2025)

Total liabilities of Novartis AG from 1998 to 2025. This chart illustrates how Novartis AG's total liabilities have evolved over time, based on quarterly financial data. Explore NOVN long-term investment intensity to see how much of total assets are deployed in long-term investments.

Novartis AG Competitors by Total Liabilities

The table below lists competitors of Novartis AG ranked by their total liabilities.

Company	Country	Total Liabilities
GE Vernova LLC NYSE:GEV	USA	$60.55 Billion
International Business Machines NYSE:IBM	USA	$117.56 Billion
BHP Group MX:BHPN	Mexico	MX$60.55 Billion
Siemens Aktiengesellschaft XETRA:SIE	Germany	€92.39 Billion
American Express Company NYSE:AXP	USA	$274.90 Billion
Linde plc Ordinary Shares NASDAQ:LIN	USA	$47.73 Billion
Citigroup Inc. NYSE:C	USA	$2.57 Trillion
Toronto Dominion Bank TO:TD	Canada	CA$1.98 Trillion

Liability Composition Analysis (1998–2025)

This chart breaks down Novartis AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Novartis AG asset portfolio.

Liquidity & Leverage Metrics

Novartis AG Total Liabilities Ratios Explained

Novartis AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	0.85	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.67	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novartis AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novartis AG (1998–2025)

The table below shows the annual total liabilities of Novartis AG from 1998 to 2025.

Year	Total Liabilities	Change
2025-12-31	CHF68.97 Billion ≈ $87.20 Billion	+18.68%
2024-12-31	CHF58.12 Billion ≈ $73.48 Billion	+9.26%
2023-12-31	CHF53.20 Billion ≈ $67.25 Billion	-8.33%
2022-12-31	CHF58.03 Billion ≈ $73.37 Billion	-9.29%
2021-12-31	CHF63.97 Billion ≈ $80.88 Billion	-10.04%
2020-12-31	CHF71.11 Billion ≈ $89.90 Billion	+13.20%
2019-12-31	CHF62.82 Billion ≈ $79.42 Billion	-6.06%
2018-12-31	CHF66.87 Billion ≈ $84.54 Billion	+13.63%
2017-12-31	CHF58.85 Billion ≈ $74.40 Billion	+6.55%
2016-12-31	CHF55.23 Billion ≈ $69.83 Billion	+1.47%
2015-12-31	CHF54.43 Billion ≈ $68.82 Billion	-0.20%
2014-12-31	CHF54.54 Billion ≈ $68.96 Billion	+5.33%
2013-12-31	CHF51.78 Billion ≈ $65.47 Billion	-5.73%
2012-12-31	CHF54.93 Billion ≈ $69.44 Billion	+6.54%
2011-12-31	CHF51.56 Billion ≈ $65.18 Billion	-3.72%
2010-12-31	CHF53.55 Billion ≈ $67.70 Billion	+40.76%
2009-12-31	CHF38.04 Billion ≈ $48.10 Billion	+36.54%
2008-12-31	CHF27.86 Billion ≈ $35.23 Billion	+6.93%
2007-12-31	CHF26.06 Billion ≈ $32.94 Billion	-2.46%
2006-12-31	CHF26.71 Billion ≈ $33.77 Billion	+8.73%
2005-12-31	CHF24.57 Billion ≈ $31.06 Billion	+16.03%
2004-12-31	CHF21.17 Billion ≈ $26.77 Billion	+12.63%
2003-12-31	CHF18.80 Billion ≈ $23.77 Billion	+12.63%
2002-12-31	CHF16.69 Billion ≈ $21.10 Billion	+13.18%
2001-12-31	CHF14.75 Billion ≈ $18.64 Billion	+11.97%
2000-12-31	CHF13.17 Billion ≈ $16.65 Billion	-25.33%
1999-12-31	CHF17.64 Billion ≈ $22.30 Billion	-1.49%
1998-12-31	CHF17.90 Billion ≈ $22.63 Billion	--

About Novartis AG

SW:NOVN Switzerland Drug Manufacturers - General

Market Cap

$323.88 Billion

CHF256.18 Billion CHF

Market Cap Rank

#92 Global

#3 in Switzerland

Share Price

CHF134.26

Change (1 day)

+2.10%

52-Week Range

CHF100.42 - CHF134.26

All Time High

CHF134.26